Tag: Regorafenib

Originally approved by the FDA in 2012 for metastatic colorectal cancer, a key question for patients and caregivers is, What is another name for Regorafenib? The answer is its brand name, Stivarga, an oral multi-kinase inhibitor developed by Bayer.

Regorafenib, a potent oral multi-kinase inhibitor, leverages a distinct and multi-pronged approach to inhibit cancer progression by targeting multiple signaling pathways critical for tumor growth, angiogenesis, and metastasis. Unlike traditional cytotoxic chemotherapy, its unique mechanism of action focuses on blocking specific proteins, providing a targeted therapeutic effect.